5-OMe-UDP is a Potent and Selective P2Y6-Receptor Agonist

Journal of Medicinal Chemistry

Volumn 53, Issue 4, 2010, Pages 1673-1685

  Ginsburg Shmuel, Tamar ^a   Haas, Michael ^b   Schumann, Marien ^b   Reiser, Georg ^b   Kalid, Ori ^a   Stern, Noa ^a   Fischer, Bilha ^a  

^a BAR ILAN UNIVERSITY   (Israel)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 OME URIDINE DIPHOSPHATE; PURINERGIC P2Y RECEPTOR; PURINERGIC P2Y RECEPTOR AGONIST; PURINERGIC P2Y2 RECEPTOR; PURINERGIC P2Y4 RECEPTOR; PURINERGIC P2Y6 RECEPTOR; PYRIMIDINE NUCLEOTIDE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE; URIDINE TRIPHOSPHATE;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG ACTIVITY; PROTEIN EXPRESSION;

CALCIUM; CELL LINE, TUMOR; HUMANS; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR CONFORMATION; RECEPTORS, PURINERGIC P2; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION; URIDINE DIPHOSPHATE;

EID: 77649207345     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901450d     Document Type: Article

References (47)

1. Abbracchio, M. P.; Burnstock, G.; Boeynaems, J.; Barnard, E. A.; Boyer, .J. L.; Kennedy, C.; E., K. G.; Fumagalli, M.; Gachet, C.; Jacobson, K. A.; Weisman, G. A. International Union of Pharmacology LVIII: Update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol. Rev. 2006, 58, 281-341.
2. Yerxa, B. R.; Sabater, J.R.; Davis, C. W.; Stutts, M. J.; Lang-Furr, M.; Picher, M.; Jones, A. C.; Cowlen, M.; Dougherty, R.; Boyer, J.; Abraham, W. M.; Boucher, R. C. Pharmacology of INS37217 [P1-(uridine 5')-P4-(2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y2 receptor agonist for the treatment of cystic fibrosis. J. Pharmacol. Exp. Ther. 2002, 302, 871-880.
3. Pintor, J.; Peral, A.; Pelaez, T.; Carracedo, G.; Bautista, A.; Hoyle, C. H. V. Nucleotides and dinucleotides in ocular physiology: New possibilities of nucleotides as therapeutic agents in the eye. Druz Dev. Res. 2003, 59, 136-145.
4. Schnurr, M.; Toy, T.; Stoitzner, P.; Cameron, P.; Shin, A.; Beecroft, T.; Davis, I. D.; Cebon, J.; Maraskovsky, E. ATP gradients inhibit the migratory capacity of specific human dendritic cell types: Implications for P2Y11 receptor signaling. Blood 2003. 102, 613-620. (Pubitemid 36841983)
5. Agteresch, H. J.; van Rooijen, M. H. C.; van den Berg, J. W. O.; Minderman-Voortman, G. J.; Wilson, J. H. P.; Dagnelie, P. C. Growth inhibition of lung cancer cells by adenosine 5'-triphosphate. Drug Dev. Res. 2003, 60, 196-203. (Pubitemid 37351791)
6. Robaye, B.; Ghanem, E.; Wilkin, F.; Fokan, D.; Van, Driessche, W.; Schurmans, S.; Boeynaems, J.-M.; Beauwens, R. Loss of nucleotide regulation of epithelial chloride transport in the jejunum of P2Y4-null mice. Mol. Pharmacol. 2003, 63, 777-783. (Pubitemid 36368983)
7. Besada, P.; Shin, D. H.; Costanzi, S.; Ko, H.; Mathe, C.; Gagneron, J.; Gosselin, G.; Maddileti, S.; Harden, T. K.; Jacobson, K. A. Structure-activity relationships of uridine 5'-diphosphate analogues at the human P2Y6 receptor. J. Med, Chem. 2006, 49, 5532-5543.
8. Somers, G. R.; Hammet, F. M. A.; Trute, L.; Southey, M. C.; Venter, D. J. Expression of the P2Y6 purinergic receptor in human T cells infiltrating inflammatory bowel disease. Lab. Invest. 1998, 78, 1375-1383.
9. Brunschweiger, A.; Muller, C. E. P2 receptors activated by uracil nucleotides-an update. Curr. Med. Chem. 2006 ,13, 289-312.
10. El-Tayeb, A.; Qi, A.; Muller, C. E. Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors. J. Med. Chem. 2006, 49, 7076-7087.
11. Jacobson, K. A.; Costanzi, S.; Ivanov, A. A.; Tchilibon, S.; Besada, P.; Gao, Z.-G.; Maddileti, S.; Harden, T. K. Structure activity and molecular modeling analyses of ribose- and base-modified uridine 5-triphosphate analogues at the human P2Y2 and P2Y4 receptors. Biochem. Pharmacol. 2006, 71, 540-549.
12. Jacobson, K. A.; Ivanov, A. A.; Castro, S.; Harden, T. K.; Ko, H. Development of selective agonists and antagonists of P2Y receptors'.' Purinergic Signalling 2009, 5, 75-89.
13. Shaver, S. R.; Rideout, J. L.; Pendergast, W.; Douglass, J. G.; Brown, E. G.: Boyer. J. L.; Patel. R. L.; Redick, C. C.; Jones, A. C.; Piclier, M.; Yerxa, B. R. Structure-activity relationships of dinucleotides: Potent and selective agonists of P2Y receptors. Puriner- gic Signalling 2005, 1, 183-191.
14. Ivanov, A. A.; Ko, H.; Cosyn, L.; Maddileti, S.; Besada, P.; Fricks, L.; Costanzi, S.; Harden, T. K.; Van, Calenbergh, S.; Jacobson, K. A. Molecular modeling of the human P2Y2 receptor and design, of a selective agonist. 2'-amino-2'-deoxy-2-thiouridine 5'-triphosphate. J. Med. Chem. 2007, 50, 1166-1176.
15. Knoblauch, B. H. A.; Muller, C. E.; Jarlebark, L.; Lawoko, G.; Kottke, T.; Wikstrom, M. A.; Heilbronn, E. 5-Substituted UTP derivatives as P2Y2 receptor agonists. Eur. J. Med. Chem. 1999, 34, 809-824. (Pubitemid 29533849)
16. Communi, D.; Parmentier, M.; Boeynaems, J.-M. Cloning, functional expression, and tissue distribution, of the human P2Y6 receptor. Biochem. Biophys. Res. Commun. 1996, 222, 303-308. (Pubitemid 26335011)
17. Nicholas, R. A.; Watt, W. C.; Lazarowski, E. R.; Li, Q.; Harden, T. K. Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: identification of a UDP-selective, a UTP-selective, and an, ATP- and UTP-specific receptor. Mol. Pharmacol. 1996, 50, 224-229.
18. Korcok, J.; Raimundo, L. N.; Du, X.; Sims, S. M.; Dixon, S. J. P2Y6 nucleotide receptors activate NF-kB and increase survival of osteoclasts. J. Biol. Chem. 2005, 280, 16909-16915.
19. Costanzi, S.; Joshi, B. V.; Maddileti, S.; Mamedova, L.; GonzalezMoa, M. J.; Marquez, V. E.; Harden, T. K.; Jacobson, K. A. Human P2Y6 receptor: molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference. J. Med. Chem. 2005, 48, 8108-8111.
20. Kim, H. S.; Ravi, R. G.; Marquez, V. E.; Maddileti, S.; Wihlborg, A.-.K.; Erlinge D.; Malmsjoe, M.; Boyer, J. L.; Harden, T. K.; Jacobson, K. A. Methanocarba modification of uracil and adenine nucleotides: high potency of northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors. J. Med. Chem. 2002, 45, 208-218.
21. Hayakawa, H.; Tanaka, H.; Miyasaka, T. Lithiation of 5,6-dihydrouridine a new route to 5-substituted uridines. Tetrahedron 1985, 41, 1675-1683.
22. Hayakawa, H.; Tanaka, H.; Obi, K.; Itoh, M.; Miyasaka, T. A simple and general entry to 5-substituted uridines based on regioselective lithiation controlled by a protecting group in the sugar moiety. Tetrahedron Lett. 1987, 28, 87-90.
23. Hayakawa, H.; Tanaka, H.; Maruyama, Y.; Miyasaka, T. Regioselectivity in the lithiation of uridine. Effect of the sugar protecting groups. Chem. Lett. 1985, 1401-1404.
24. Evans, M. E.; Parrish, F. W.; Long, L., Jr. Acetal exchange reactions. Carbohydr. Res. 1961, 3, 453-462.
25. Tanaka, H.; Hayakawa, H.; Miyasaka, T. Umpolung of reactivity at the C-6 position of uridine: a simple and general method for 6-substituted uridines. Tetrahedron 1982, 38, 2635-2642.
26. Tanaka, H.; lijima, S.; Matsuda, A.; Hayakawa, H.; Miyasaka, T.; Ueda, T. The reaction of 6-phenylthiouridine with, sulfur nucleophiles: a simple and regiospecific preparation of 6-alkylthiouridines and 6-alkylthiouridylic acids. Chem. Pharm. Bull. 1983, 31, 1222-1227.
27. Halbfinger, E.; Major, D. T.; Ritzmann, M.; Ubl, J.; Reiser, G.; Boyer, J. L.; Harden, K. T.; Fischer, B. Molecular recognition of modified adenine nucleotides by the P2Y1-receptor. 1. A synthetic, biochemical, and, NMR approach. J. Med, Chem. 1999, 42, 5325-5337. (Pubitemid 30036768)
28. Saenger, W. Principles of Nucleic Acid Structure; Springer-Verlag: New York, 1984; pp 107-110.
29. Donohue, J.; Tmeblood, K. N. Base pairing in DNA. J. Mol. Biol. 1960, 2, 363-371.
30. Sundaralingam, M. Stereochemistry of nucleic acids and their constituents. IV. Allowed and preferred conformations of nucleosides, nucleoside mono-, di-, tri-, tetraphosphates, nucleic acids, and polynucleotides. Biopolymers 1969, 7, 821-860.
31. Altona, C.; Sundaralingam, M. Conformational analysis of the sugar ring in nucleosides and nucleotides. Improved method for the interpretation of proton magnetic resonance coupling constants. J. Am. Chem. Soc. 1973, 95, 2333-2344.
32. Davies, D. B.; Danyluk S. S. Nuclear magnetic resonance studies of 5'-ribo- and deoxyribonucleotide structures in solution. Biochemistry 1974, 13, 4417-4434.
33. Prado,F.R.;Giessner-Prettre,C.;Pullman,B. Ontheconformationaldependenceoftheprotonchemicalshiftsinnucleosidesand nucleotides.III.Protonchemicalshiftsof5'- nucleotidesasafunctionofdifferentconformationalparameters.J.Theor.Biol.1978,74, 259-277.(Pubitemid9040773)
34. Schweizer, M. P.; Banta, E. B.; Witkowski, J. T.; Robins, R. K. Determination of pyrimidine nucleoside syn,anti conformational preference in solution by proton and carbon-13 nuclear magnetic resonance. J. Am. Chem. Soc. 1973, 95, 3770-3778.
35. Ippel, J. H.; Wijmenga, S. S.; de Jong, R.; Heus, H. A.; Hilbers, C. W.; de Vroom, E.; van der Marel, G. A.; van Boom, J. H. Heteronuclear scalar couplings in the bases and sugar rings of nucleic acids: their determination and application in assignment and conformational analysis. Magn. Reson. Chem. 1996, 34, S156-S176.
36. Suck, D.; Saenger, W.; Vorbrüggen, H. Conformation of 6-methyluridine, a pyrimidine nucleoside in the syn conformation. Nature 1972, 235, 333-334.
37. Altona, C.; Sundaralingam, M. Conformational analysis of the sugar ring in nucleosides and nucleotides. A new description using the concept of pseudorotation. J. Am. Chem. Soc. 1972, 94, 8205-8212.
38. Blackburn, B. J.; Grey, A. A.; Smith, I. C. P.; Hruska, F. E. Determination of the molecular conformation of uridine in aqueous solution by proton magnetic resonance spectroscopy. Comparison with β-pseudouridine. Can. J. Chem. 1970, 48, 2866-2870.
39. Sigel, H. Complex formation of nucleic bases with cupric ion. Acidity of N-1-protons in inosine-, guanosine-, uridine-, and thymidine 5'-triphosphates and their cupric complexes. Eur. J. Biochem. 1968, 3, 530-537.
40. Sawyer, D. T.; Heineman, W. R.; Beebe, J. M. Chemistry Experiments for Instrumental Methods; John Wiley and Sons: New York, 1984; pp 19-23.
41. Pozharskii. A. F. Heteroaromaticity. Khim. Geterotsikl. Soedin. 1985, 867-905.
42. Uhl, W.; Reiner, J.; Gassen, H. G. On the conformation of 5substituted uridines as studied by proton magnetic resonance. Nucleic Acids Res. 1983, 11, 1167-1180.
43. Burnstock, G.; Fischer, B.; Hoyle, C. H. V.; Maillard, M.; Ziganshin, A. U.; Brizzolara, A. L.; von Isakovics, A.; Boyer, J. L.; Harden, K.; Jacobson, K. A. Structure activity relationships for derivatives of adenosine-5'- triphosphate as agonists at P2 purinoceptors: heterogeneity within P2X and, P2Y subtypes. Druz Dev. Res. 1994, 31, 206-219.
44. Xie, D.; Li, A.; Wang, M.; Fan, Z.; Feng, H. LOCSVMPSI: a web server for subcellular localization of eukaryotic proteins using SVM and profile of PSI-BLAST. Nucleic Acids Res. 2005, 33, W105-W110.
45. i protease-activated receptors (PAR-I and PAR-2) in rat astrocytes and C6 glioma cells. Neuroscience (Oxford) 1998, 86, 597-609.
46. 11 nucleotide receptors by adenosine 5'-0-(a-boranotriphosphate) analogues. Br. J. Pharmacol. 2006. 149. 416-423.
47. 11 receptor. Biochem. J. 2008, 409, 107-116.